Xilingio 10mg/5mg Tablet is a combination oral antidiabetic medication containing Empagliflozin 10mg and Linagliptin 5mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. This dual mechanism offers improved glycemic control by targeting both renal glucose handling and pancreatic hormone regulation. Xilingio is typically prescribed as adjunctive therapy to diet and exercise when monotherapy is insufficient. It may be used alone or in combination with other antidiabetic agents. The fixed-dose combination simplifies treatment regimens, potentially enhancing patient adherence. Common adverse effects include urinary tract infections, nasopharyngitis, and hypoglycemia, particularly when used with insulin or sulfonylureas. Caution is advised in patients with renal impairment, and it is contraindicated in type 1 diabetes or diabetic ketoacidosis. Regular monitoring of renal function and blood glucose is recommended during therapy. Xilingio should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.